MedPath

The prospective study on differentiation and treatment of membranous nephropathy by Wenyang Huaji method

Not Applicable
Recruiting
Conditions
Membranous Nephropathy
Registration Number
ITMCTR2100004443
Lead Sponsor
Beijing Hospital of TCM
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1.Conforms to the MN diagnostic criteria.
2.Conforms to the diagnostic criteria of Shaoyin Taiyin syndrome.
3.The patient has signed the informed consent.
4.Between the ages of 18 and 75.
5.CKD stage I-III, eGFR > 30ml/min, serum albumin > 15g/L.

Exclusion Criteria

1. Progressive membranous nephropathy (progressive decrease of renal function;Kidney biopsy showed necrotizing capillaritis and > 50% large crescent), accompanied by IgA nephropathy, diabetic nephropathy and other kidney diseases.
2. Confirmed by hepatitis B, systemic lupus erythematosus, tumor, drug damage and other factors secondary and need to actively treat the primary disease, such as active hepatitis B and persistent liver function test transaminase abnormalities, or anti-nuclear antibodies, double Abnormal strand DNA, ANCA or other indicators of immune disease.
3. With acute central nervous system disease, severe gastrointestinal disease, a history of HIV infection, a history of mental illness or a history of malignancy.
4. With other organ diseases and dysfunction, and with life-threatening complications such as severely infected persons.
5. Pregnant or lactating women.
6. Other clinical trials are under study.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
24-hour urine protein;serum albumin;
Secondary Outcome Measures
NameTimeMethod
Anti-PLA2R Antibody;Total Cholesterol;TCM syndrome scores;Triglyceride;
© Copyright 2025. All Rights Reserved by MedPath